Randomized Trialhigh evidence
Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.
The New England journal of medicine·October 23, 2026·PMID 42912669
Why it mattersIgA nephropathy often progresses despite standard supportive care, and proteinuria reduction is a key surrogate for renal outcomes. Povetacicept's dual BAFF/APRIL inhibition targets a pathogenic pathway, offering a potential disease-modifying option beyond current immunosuppression.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled